September 13, 2006 -- Bristol-Myers Squibb signed a deal with Medivir of Sweden to develop an HIV drug; New River completed enrolling adult patients in a trial of its lead ADHD drug; an FDA advisory committee chose not to recommend approval of Factive from Oscient; Vical received a US patent for Vaxfectin, a vaccine adjuvant; Hollis-Eden said its steroid compounds produced positive data in preclinical testing against prostate cancer; Cardiome reported mixed data on its atrial fibrillation drug; and Abbott launched its Emboshield device in Europe. The Centient Biotech 200™ was 4 points higher at 3717.63, a rise of .10%. More details...
